EUCTR2004-003771-37-HU进行中（未招募）不适用
A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs. - HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Genmab A/S
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Males and females = 18 years
- •2) A diagnosis of rheumatoid arthritis according to the American College of Rheumatology (ACR) of at least six months duration
- •3) Active disease at the time of screening as defined by :
- •- Six or more swollen joins (of 28 joints)
- •- Six or more tender joints (of 28 joints)
- •- Erythrocyte Sedimentation Rate (ESR) = 22 mm/h (using Becton Dickinson Seditainer) and/or C-Reactive Protein (CRP) = 10 mg/L (1 mg/dL)
- •4) RA functional class I, II, or III
- •5) Treatment failure to one or more DMARDs.
- •- Treatment failure is defined as either intolerance at any time or insufficient efficacy after a minimum of 12 weeks of DMARD treatment.
- •- DMARDs include, among others, methotrexate, hydroxychloroquine, chloroquine, gold preparations, azathioprine, D-penicillamine, sulfasalazine, minocycline, leflunomide, and cyclosporine A.
- •6) Applicable only to patients on methotrexate therapy at time of screening: Treatment with methotrexate for at least 12 weeks prior to planned start of trial treatment (Visit 2), with possible interruption of treatment of maximum two weeks in total, in the period 5-12 weeks from Visit 2.
- •7) Applicable only to patients on methotrexate therapy at time of screening: Treatment with a stable dose of methotrexate (7.5 – 25 mg/week, p.o., i.m., and/or s.c.) for at least four weeks prior to planned start of trial treatment (Visit 2)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Use of DMARDs (other than methotrexate, if patient is on methotrexate treatment at time of screening): = 4 weeks prior to planned start of trial treatment (Visit 2).If patient is not on methotrexate treatment at time of screening: Methotrexate = 4 weeks prior to planned start of trial treatment (Visit 2). Specifically for leflunomide treatment: Use of leflunomide =12 weeks prior to planned start of trial treatment (visit 2) unless the patient has completed peroral cholestyramine treatment for washout, according to locally accepted clinical practices.
- •2) Exposure to other biological products (e.g. etanercept, infliximab, adalimumab, and kineret) within 4 weeks prior to planned start of trial treament (Visit 2), and/or exposure to anti-CD20 antibodies within two years before screening for this trial
- •3) Any use of cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents within five years before screening for this trial
- •4) Within four weeks prior to planned start of trial treatment (Visit 2):
- •- Treatment with oral corticosteroids ( > 10 mg prednisolone per day or equivalent)
- •- Start of oral corticosteroid treatment
- •- Change in any ongoing oral corticosteroid dose
- •5) Use of intra-articular, i.m. or i.v. corticosteroids (including i.m. adrenocorticotrophe hormone) within four weeks prior to planned start of trial treatment (Visit 2)
- •6) Active autoimmune disease (other than RA and RA-associated secondary diseases) requiring immunosuppressive therapy
- •7) Diagnosis of fibromyalgia or other chronic pain syndrome requiring daily narcotic treatment
- •8) Past or current malignancy, except for
- •- Resected cervical carcinoma Stage 1B or less
- •- Resected non-invasive basal cell and squamous cell skin carcinoma
- •- Malignant melanoma with a complete response of a duration of > 10 years
- •- Other cancer diagnoses with a complete response of a duration of > 5 years
- •9) Chronic or current infectious disease such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, sinusitis, and tuberculosis
- •10) History of infected joint prosthesis within five years before Visit 1 and infected native joints within one year before Visit 1
- •11) Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
- •12) Significant concurrent uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease
- •13) History of significant cerebrovascular disease
- •14) Screening laboratory values:
- •- Hemoglobin < 6.2 mmol/L (9.9 g/dL)
- •- Neutrophils < 2 x 109/ L
- •- Platelets < 100 x 109/ L
- •- S-ALAT > 1.5 times the upper limit of normal
- •- S-ALP > two times the upper limit of normal
- •- S-creatinine > 133 µmol/L (1.5 mg/dL)
- •15) Known or suspected positive serology for HIV
- •16) Positive serology for hepatitis B or C
- •17) Patients previously screened for this trial, unless reason for previous screen failure was failure to fulfill inclusion criterion no. 3
- •18) Current or previous (within four weeks of screening) participation in any other clinical trial
- •19) Patients known or suspected to be unable to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- •20) Breast feeding women or women with a positive
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease. - ELTODYS09Dyskinesias related to levodopa treatment in Parkinson´s diseaseEUCTR2009-015928-28-SEPsychoGenics Inc24
招募中
1 期
Dose-finding study of SAR443122 in adult participants with ulcerative colitisColitis ulcerativeMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2022-500290-14-01Sanofi-Aventis Research & Development311
招募中
2 期
A Global Phase-III Clinical Trial to be conducted in adult population who are suffering from moderate to severe ulcerative colitis to evaluate the efficacy and safety of Test Drug (SAR443122) vs Placebo.CTRI/2023/06/053613Sanofi-Aventis Recherche & Développement
终止
2 期
A randomized, double-blind, placebo controlled, dose ranging study to assess the safety, tolerability, and efficacy of HTL0018318 in patients with dementia with Lewy bodies.Dementia with Lewy bodies (DLB)JPRN-jRCT2080223932Sosei Co. Ltd. (Global sponsor: Heptares Therapeutics Limited)172
招募中
2 期
Dose-finding study of SAR443122 in adult participants with ulcerative colitisColitis ulcerativeJPRN-jRCT2031230203Tanaka Tomoyuki182